PFIZER pushes for boosters…

Pfizer told the FDA Wednesday that data from its clinical trials suggests a third shot of its coronavirus vaccine may be necessary six months after the second dose because of waning efficacy.

Why it matters: The FDA’s advisory committee on Friday is expected to review Pfizer’s clinical trials and other supporting and conflicting data on coronavirus booster shots and make recommendations on whether more Americans 16 years and older should receive an extra dose.

Pfizer included the clinical trial data in a presentation that it will deliver to the advisory committee.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Send this to a friend